- Home
- PRU vs TAK Comparison
PRU vs TAK Comparison
Compare PRU & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRU | TAK |
|---|---|---|
| Founded | 1875 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5B | 43.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRU | TAK |
|---|---|---|
| Price | $113.11 | $15.61 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $118.00 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 2.4M |
| Earning Date | 02-03-2026 | 01-29-2026 |
| Dividend Yield | ★ 4.78% | 3.38% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.27 | 0.14 |
| Revenue | ★ $57,598,000,000.00 | $29,846,840,032.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.81 | $0.47 |
| P/E Ratio | ★ $15.52 | $218.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $90.38 | $12.80 |
| 52 Week High | $123.88 | $15.78 |
Technical Indicators
Market Signals| Indicator | PRU | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 73.03 |
| Support Level | $112.83 | $14.43 |
| Resistance Level | $118.31 | $15.78 |
| Average True Range (ATR) | 1.52 | 0.17 |
| MACD | -0.58 | 0.10 |
| Stochastic Oscillator | 2.68 | 88.67 |
Price Performance
Historical ComparisonAbout PRU Prudential Financial Inc.
Prudential Financial is one of the largest US life insurers, offering annuities, life insurance, and asset-management products. The United States and Japan are its two largest markets. Its US business contributed about 50% of adjusted 2024 earnings and includes institutional retirement (mostly pension risk transfer), individual retirement (annuities), group insurance, and individual life insurance. Its international business represented about 40% of adjusted earnings, with a strong market position in Japan, and the firm also has a presence in emerging markets like Brazil. The company's investment management business, PGIM, contributed approximately 10% of its 2024 adjusted earnings and has around $1.4 trillion in assets under management.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.